Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 19/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85981 | 1.00 | SLC22A2 (0.75) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL18462050 | 1.00 | SLC22A2 (0.75) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19071752 | 1.00 | SLC22A2 (0.75) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL85979 | 0.98 | SLC22A2 (0.75) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19677101 | 0.89 | SLC22A2 (0.78) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL16391402 | 0.89 | SLC22A2 (0.78) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19677179 | 0.89 | SLC22A2 (0.78) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19313811 | 0.89 | SLC22A2 (0.78) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL21219801 | 0.89 | SLC22A2 (0.78) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19313935 | 0.89 | SLC22A2 (0.78) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3187225-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3372281-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3284520-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3045206-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3284520-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV Healthcare Company (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3284519-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV Healthcare Company (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170224695-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-3187225-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV Healthcare Company (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-3187226-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV Healthcare Company (US) | 2017-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224695-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NCOA4, NR4A1, NR4A2 | SLC22A2 3012/4885CYP3A4 26/4885TMEM97 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.